408 results
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Survival #EBM #Honc ... #Osimertinib #NSCLC ... #Survival #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Lung Cancer #EBM #Honc ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Diagnostic Algorithm for Non–Small-Cell Lung Cancer (NSCLC). The upper portion of the algorithm shows the morphologic
Non–Small-Cell Lung Cancer (NSCLC ... classification of NSCLC ... #Diagnosis #Honc ... #Algorithm #NSCLC ... #PDL1 #NEJM
Early Events in Acute GVHD #Pathophys #Honc #GVHD #GraftVersusHostDisease #NEJM
GVHD #Pathophys #Honc ... GraftVersusHostDisease #NEJM
Possible Mechanisms Underlying Immune-Related Adverse Events #Pathophys #Honc #ImmuneRelatedAdverseEvents #Immunotherapy #NEJM
Events #Pathophys #Honc ... Immunotherapy #NEJM
Causes of SVC Syndrome - Differential Diagnosis Framework
 • Benign (15-40%): Thrombosis (aka catheter-associated), Goiter, Fibrosing
Malignant (60-85%): SCLC ... , NSCLC, NHL, Germ
The Pathway of Heme Synthesis, Showing Pathway Intermediates and End-Product Regulation by Heme #Pathophys #Honc #Heme
Heme #Pathophys #Honc ... Synthesis #Porphyria #NEJM
Biologic Events Leading to Chronic GVHD #Pathophys #Honc #Pharm #GVHD #GraftVersusHostDisease #Therapeutic #Pathways #NEJM
GVHD #Pathophys #Honc ... Therapeutic #Pathways #NEJM
Role of G6PD in Protection against Oxidative Damage #Pathophys #Peds #Genetics #Honc #Favism #g6pd #NEJM
Peds #Genetics #Honc ... #Favism #g6pd #NEJM